// App-Quantinova.ai

: The utility of PD-L1 as a prognostic marker in pancreatic ductal adenocarcinoma (PDAC).

Researchers

Presenter

  • Linda Wu

Principal Investigators

  • Daniel Jeremy Fulop

  • Michelle Rudshteyn

  • Nagma Shah

  • Michael Hill-Oliva

  • Sophie Sohval

  • Sonal Gandhi

  • Nobel Chowdhury

  • Neha Debnath

  • Deirdre Jill Cohen

Medical Centers

  • Elmhurst Hospital Center, Icahn School of Medicine at Mount Sinai, New York, NY

  • Mount Sinai Morningside West, Icahn School of Medicine at Mount Sinai, New York, NY

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Mount Sinai Morningside West, Icahn School of Medicine at Mount Sinai, New York, NY

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Icahn School of Medicine at Mount Sinai Morningside/West, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Microphthalmia, syndromic, 9

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved